Sun Pharmaceuticals

Global ambition as Sun Pharma explores large-scale overseas expansion amid Organon speculation

By Axel Miller | 27 Apr 2026

Reports of Sun Pharma acquiring Organon highlight India’s global pharma ambitions, but no deal is confirmed. Explore what’s real and what’s speculation.

Sun Pharma Gets DCGI Nod for Generic Wegovy, Set for March Launch as Semaglutide Patent Nears Expiry

By Axel Miller | 23 Jan 2026

Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the semaglutide patent expires in March 2026.

Sun Pharma Advanced Research to Cut Workforce by 40% in Cost Optimisation Push

By Axel Miller | 08 Jan 2026

SPARC slashes 40% of workforce and consolidates labs to save $10M annually. Discover how the Sezaby PRV ruling could clear the firm’s $46M debt.

Sun Pharma to acquire oncology therapy company Checkpoint in US

11 Mar 2025

Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology company, Checkpoint Therapeutics Inc

Taro to merge with Sun Pharma in $350 million deal

21 Jan 2024

Sun Pharmaceutical Industries Limited and Israel-based Taro Pharmaceutical Industries Ltd have entered into a definitive merger agreement under which Sun Pharma

Sun Pharma chairman Israel Makov to retire on 29 August

08 Aug 2022

Makov has played a significant role in Sun Pharma’s transformation from a $1.7 billion organisation focusing on India and the US into the world's fourth largest specialty generic pharmaceutical company operating across 100+ markets with a turnover of over $5 billion